Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
For women looking to address the visceral fat shift of menopause without the appetite suppression and gastrointestinal effects of GLP-1 agonists, AOD-9604 deserves serious consideration
This hormone helps regulate blood sugar levels, promotes feelings of fullness, and supports weight management
The Phase 2 trial included DEXA scans to measure changes in fat mass and lean mass
Within the GLP-1 receptor agonist class , other options available in the UK include: Dulaglutide (Trulicity) weekly injection with proven cardiovascular benefits [12] [17] Liraglutide (Victoza) daily injection with proven cardiovascular benefits [13] Exenatide (Byetta) twice-daily injection Exenatide extended-release (Bydureon) weekly injection Lixisenatide (Lyxumia) daily injection Tirzepatide (Mounjaro) weekly injection that acts on both GLP-1 and GIP receptors [14] [15] Whilst these medications share similar mechanisms to semaglutide, individual tolerability varies
